Overcoming the bottleneck: Why the transition from clinical trial to market supply determines success

The path of a pharmaceutical product from development to the patient is a marathon, not a sprint. Yet often, just before the finish line — at the transition from the clinical phase (investigational medicinal products) to commercial market supply — unnecessary friction losses occur.

Many pharmaceutical companies work with specialised small suppliers during the clinical phase. As soon as approval is within reach, the search begins for a partner for large-scale production. This change costs time, requires new knowledge transfer and carries regulatory risks.

Our USP: Scalability as a strategy
At Complex Pharmaceuticals, we have integrated this process. We are not merely a ‘contract packager’ — we are your strategic partner for the entire product lifecycle.

1. The clinical phase: We master the complexity of clinical trial materials, from the precise labelling of the smallest batches through to the timely provision for clinical centres.
2. The seamless transition: Since our facilities are modularly structured, we can scale the same technology that we use for clinical samples to the commercial series without extensive process changes — and also store and commission your products in large quantities on call.
3. Knowledge stays in-house: The validations and process knowledge from the study phase flow directly into market supply. This drastically shortens the ‘time to market’.

Why this matters for the location
Supply security does not begin in the pharmacy shelf, but already in product development. If we pool the competence in Austria to transfer clinical innovations directly into production, we strengthen the entire European resilience.

At Complex Pharmaceuticals, we offer precisely this bridge: flexible enough for highly specialised research projects, powerful enough for the broad market.

FAQ

1. What advantages does handling clinical trial materials at Complex Pharmaceuticals offer? We understand the high requirements for precise labelling and blinding of investigational medicinal products. Through our GMP-compliant processes and the flexible plant structure, we can implement even highly complex packaging designs for clinical trials at short notice and with assurance — regardless of the quantity.
2. Why is it beneficial to stay with the same partner after the clinical phase? A change of partner after approval often means: time- and cost-intensive audits, knowledge transfer and new validations. With us, process knowledge stays in-house. We scale the packaging from the clinical phase directly up to the commercial series. This saves months of time and reduces regulatory risk.
3. How does Complex Pharmaceuticals ensure quality during scale-up? Since we already apply the same technological standards and quality management systems in the clinical phase as in commercial production, the transition is seamless. Our experts accompany the product throughout the entire lifecycle and thereby ensure consistent GxP compliance.